EUVIMEDEUVIMED entdecken
Crossref

A genome-wide association study of escitalopram treatment outcomes in patients with major depressive disorder

Siyu Ren, He Peng, Jinniu Zhang, Jian Yang, Yi He, Zuoli Sun, Gang Wang

Gene · 2024

DOI: 10.1016/j.gene.2024.148596 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Gene, 2024. Verfasst von Siyu Ren und 6 weiteren Autor:innen. Beteiligte Einrichtung: The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical Uni…. Hauptthemen laut MEDLINE: Major Depressive Disorder, Genome-Wide Association Study, Escitalopram. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Major depressive disorder (MDD) is a common psychological condition, the consequences of which, such as suicide, can be severe. Escitalopram, a selective serotonin reuptake inhibitor, is a commonly used antidepressant in clinics. However, more than one-third of patients with MDD do not respond to this drug. Gene polymorphism may affect the efficacy of escitalopram, but the genetic architecture of the antidepressant response in patients with MDD remains unclear. We perform a genome-wide association study (GWAS) of the genetic effect on the outcome of escitalopram in patients with MDD. A total of 203 patients with MDD and 176 healthy control (HC) adults were recruited from Beijing Anding Hospital. Patients received 12 weeks of antidepressant treatment with escitalopram. The Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR) or Hamilton depression scale (HAMD) were used to evaluate the severity of depression symptoms at the baseline and the end of 2 and 12 weeks of treatment. A total of 140 variants in MDD patients were identified by GWAS to have genome-wide significance (p < 5e - 8) compared with HCs. Similarly, 189 and 18 variants were identified to be associated with QIDS-SR and HAMD score changes in patients after antidepressant treatment (p < 1e - 5), including rs12602361, rs72799048, rs16842235, and rs2518256. In the two weeks QIDS-SR score study, the gene-level association for these variants and gene set enrichment analyses implicate the enrichment of genes involved in the synaptic plasticity process and nervous system development. Our results implicate the predictive capacity of the effect of escitalopram treatment, supporting a link between genetic basis and remission of depression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Major Depressive DisorderGenome-Wide Association StudyEscitalopramHumansFemaleMaleAdultMiddle AgedTreatment OutcomePolymorphism, Single NucleotideSelective Serotonin Reuptake InhibitorsCase-Control StudiesCitalopramAntidepressive Agents

Stichwörter der Autor:innen

EscitalopramGenome-wide association studyMajor depressive disorder

Substanzen

EscitalopramSelective Serotonin Reuptake InhibitorsCitalopramAntidepressive Agents

Autor:innen und Institutionen

  • The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China; Advanced Innovation Center for Human Brain Pr…
  • The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China; Department of Computational Biology for Indiv…
  • The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Ren, S., Peng, H., Zhang, J., Yang, J., He, Y., Sun, Z., & Wang, G. (2024). A genome-wide association study of escitalopram treatment outcomes in patients with major depressive disorder. Gene. https://doi.org/10.1016/j.gene.2024.148596

Vancouver

Ren S, Peng H, Zhang J, Yang J, He Y, Sun Z, et al. A genome-wide association study of escitalopram treatment outcomes in patients with major depressive disorder. Gene. 2024. doi:10.1016/j.gene.2024.148596

BibTeX
@article{Ren2024,
  author = {Ren, Siyu and Peng, He and Zhang, Jinniu and Yang, Jian and He, Yi and Sun, Zuoli and Wang, Gang},
  title = {A genome-wide association study of escitalopram treatment outcomes in patients with major depressive disorder},
  journal = {Gene},
  year = {2024},
  doi = {10.1016/j.gene.2024.148596}
}
Kostenlos starten →